NDAORALPOWDERPriority Review
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is hiv protease inhibitors [moa]. First approved in 2017.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral HIV protease inhibitor that blocks HIV replication by inhibiting the protease enzyme required for viral maturation. It is primarily used as a pharmacokinetic booster in combination antiretroviral regimens rather than as a primary antiretroviral agent. Ritonavir works by inhibiting cytochrome P450 3A, which increases and prolongs the blood levels of other protease inhibitors.
$0.753MPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization, suggesting stable maintenance-focused commercial operations rather than growth-stage expansion.
Mechanism of Action
HIV Protease Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
HIV Infections
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
1,300 enrolled
HIV Infections
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
14 enrolled
HIV InfectionsPregnancy
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
29 enrolled
HIV Infections
The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment
100 enrolled
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.